Transdermal penetrant formulations containing cannabidiol

Abstract

Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides and ii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.

1 - 61 . (canceled) 
     
     
         62 . A method of treating a patient with a mental health, neurological, autoimmune or pain disease by applying a transdermal formulation to the skin of the patient, the transdermal formulation comprising the following components:
 a. a Cannabidiol at a concentration from 1% to 7%;   b. a phosphatidylcholine at a concentration from 4% to 15%;   c. glucose at a concentration from 0% to 3%   d. benzyl alcohol at a concentration from 0.25% to 5%;   e. deionized water at a concentration from 10% to 75%;   f. safflower oil at a concentration from 1% to 20%;   g. oleic acid at a concentration from 0.2% to 7.5%;   h. stearic acid at a concentration from 0.1% to 7%; and   i. isopropyl palmitate at a concentration from 5% to 30%.   
     
     
         63 . The method of  claim 62 , wherein the Cannabidiol is at a concentration from 1.5% to 6%. 
     
     
         64 . The method of  claim 62 , wherein the transdermal formulation further comprises one or more of a moisturizer, cream, oil or lotion. 
     
     
         65 . The method of  claim 62 , wherein the transdermal formulation further comprises a surfactant. 
     
     
         66 . The method of  claim 62 , wherein the transdermal formulation further comprises a nonionic detergent. 
     
     
         67 . The method of  claim 62 , wherein the transdermal formulation further comprises a polar gelling agent. 
     
     
         68 . The method of  claim 62 , wherein the transdermal formulation further comprises an antioxidant. 
     
     
         69 . The method of  claim 62 , wherein the transdermal formulation includes the Cannabidiol and one or more additional active agents to treat a mental health, neurological, autoimmune or pain disease. 
     
     
         70 . The method of  claim 62 , wherein the mental health disease is schizophrenia, post-traumatic stress syndrome or anxiety. 
     
     
         71 . The method of  claim 62 , wherein the neurological disease is fibromyalgia, epilepsy, autism, Amyotrophic Lateral Sclerosis, multiple sclerosis, cognition, sedation, spasms or seizures. 
     
     
         72 . The method of  claim 62 , wherein the pain disease is pain, severe pain, migraine or chronic neuropathic pain. 
     
     
         73 . The method of  claim 62 , wherein the autoimmune disease is Crohn’s disease, inflammation or ulcerative colitis. 
     
     
         74 . The method of  claim 62 , wherein the transdermal formulation has a pH from 4 - 6. 
     
     
         75 . The method of  claim 62 , wherein the safflower oil comprises a linoleic acid. 
     
     
         76 . A method of treating a patient by preventing, inhibiting or ameliorating a disease by applying a transdermal formulation to the skin of the patient, the transdermal formulation comprising the following components:
 a. a Cannabidiol at a concentration from 1% to 7%;   b. a phosphatidylcholine at a concentration from 4% to 15%;   c. glucose at a concentration from 0% to 3%   d. benzyl alcohol at a concentration from 0.25% to 5%;   e. deionized water at a concentration from 10% to 75%;   f. safflower oil at a concentration from 1% to 20%;   g. oleic acid at a concentration from 0.2% to 7.5%;   h. stearic acid at a concentration from 0.1% to 7%; and   i. isopropyl palmitate at a concentration from 5% to 30%  wherein the disease is a mental health, neurological, autoimmune or pain disease. 
     
     
         77 . The method of  claim 76 , wherein the treatment prevents, inhibits or ameliorates a mental health, neurological, autoimmune or pain diseases. 
     
     
         78 . The method of  claim 76 , wherein the transdermal formulation further comprises one or more additional active agents. 
     
     
         79 . The method of  claim 76 , wherein the transdermal formulation further comprises a nonionic detergent. 
     
     
         80 . The method of  claim 76 , wherein the transdermal formulation further comprises a polar gelling agent. 
     
     
         81 . The method of  claim 76 , wherein the transdermal formulation further comprises an antioxidant.